Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study

Kensei Tobinai; Toshiki Uchida; Noriko Fukuhara; Tomoaki Nishikawa

doi:10.1007/s12185-018-02577-8

Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study

Kensei Tobinai, Toshiki Uchida, Noriko Fukuhara, Tomoaki Nishikawa

大学病院・内科

研究成果: Letter › 査読

4 被引用数 (Scopus)

本文言語	English
ページ（範囲）	366-368
ページ数	3
ジャーナル	International journal of hematology
巻	109
号	3
DOI	https://doi.org/10.1007/s12185-018-02577-8
出版ステータス	Published - 2019 3月 20

ASJC Scopus subject areas

血液学

文献へのアクセス

10.1007/s12185-018-02577-8

他のファイルとリンク

引用スタイル

@article{855d3df190b94a129c1c8705f9c2492e,

title = "Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study",

author = "Kensei Tobinai and Toshiki Uchida and Noriko Fukuhara and Tomoaki Nishikawa",

note = "Funding Information: This study was funded by Janssen Pharmaceutical K.K. We thank the patients who participated in this trial and their families. Writing assistance was provided by Safeer Mughal, PhD, of PAREXEL, and was funded by Janssen Global Services. The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at https://www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu. Funding Information: Acknowledgements This study was funded by Janssen Pharmaceutical K.K. We thank the patients who participated in this trial and their families. Writing assistance was provided by Safeer Mughal, PhD, of PAREXEL, and was funded by Janssen Global Services. The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at https://www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu. Funding Information: Conflict of interest KT received grants and personal fees from Cel-gene, Chugai, Eisai, Janssen, Kyowa Hakko Kirin, Mundipharma, Ono, Takeda; personal fees from HUYA and Zenyaku Kogyo; grants from AbbVie, GSK SERVIER. NF received grants from Janssen. TU received personal fees from BMS, Celgene, Chugai, Eisai, Janssen, Kyowa Hakko Kirin, Novartis, Mundipharma, Nippon Shinyaku, Ot-suka, Pfizer Takeda. TN is employed by Janssen.",

year = "2019",

month = mar,

day = "20",

doi = "10.1007/s12185-018-02577-8",

language = "English",

volume = "109",

pages = "366--368",

journal = "International Journal of Hematology",

issn = "0925-5710",

publisher = "Springer Japan",

number = "3",

}

TY - JOUR

T1 - Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies

T2 - final analysis of phase I study

AU - Tobinai, Kensei

AU - Uchida, Toshiki

AU - Fukuhara, Noriko

AU - Nishikawa, Tomoaki

N1 - Funding Information: This study was funded by Janssen Pharmaceutical K.K. We thank the patients who participated in this trial and their families. Writing assistance was provided by Safeer Mughal, PhD, of PAREXEL, and was funded by Janssen Global Services. The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at https://www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu. Funding Information: Acknowledgements This study was funded by Janssen Pharmaceutical K.K. We thank the patients who participated in this trial and their families. Writing assistance was provided by Safeer Mughal, PhD, of PAREXEL, and was funded by Janssen Global Services. The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at https://www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu. Funding Information: Conflict of interest KT received grants and personal fees from Cel-gene, Chugai, Eisai, Janssen, Kyowa Hakko Kirin, Mundipharma, Ono, Takeda; personal fees from HUYA and Zenyaku Kogyo; grants from AbbVie, GSK SERVIER. NF received grants from Janssen. TU received personal fees from BMS, Celgene, Chugai, Eisai, Janssen, Kyowa Hakko Kirin, Novartis, Mundipharma, Nippon Shinyaku, Ot-suka, Pfizer Takeda. TN is employed by Janssen.

PY - 2019/3/20

Y1 - 2019/3/20

UR - http://www.scopus.com/inward/record.url?scp=85059685366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059685366&partnerID=8YFLogxK

U2 - 10.1007/s12185-018-02577-8

DO - 10.1007/s12185-018-02577-8

M3 - Letter

C2 - 30623356

AN - SCOPUS:85059685366

SN - 0925-5710

VL - 109

SP - 366

EP - 368

JO - International Journal of Hematology

JF - International Journal of Hematology

IS - 3

ER -